Training and carry out breakthrough research on the rapidly expanding and high impact field of cancer immunotherapy
I-DireCT, Marie Curie Innovative Training Network (ITN) is at the forefront of biotechnology research, dedicated to groundbreaking advancements in cancer immunotherapy. Through a carefully integrated academic and inter-sectoral program, I-DireCT focuses on developing next-generation immunotherapeutics and equipping early-stage researchers with the qualifications for successful careers in both academia and industry.
The mission of I-DireCT encompasses the design of innovative bispecific antibodies and immunocytokines with tumor-restricted immunostimulatory effects. Furthermore, the company is developing optimized delivery systems to ensure the optimal and timed release of bioactive drugs. Combining state-of-the-art industrial design of nanotech-based drug formulations with cutting-edge academic and industrial immunotherapeutic concepts, I-DireCT is shaping the future of cancer treatment.
Located at Hanzeplein 1, Groningen, 9713 GZ, NL, I-DireCT is committed to offering a multidisciplinary training program. This program allows young scientists to generate breakthrough ideas and take on leading positions in the field. The company’s management is actively working to complete all details about its activities. We invite the management of I-DireCT to create a customized and exclusive company showcase and product listing on our platform to further highlight its capabilities and innovations.
Other organizations in the same industry
This company is also known as